Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business day
Get my quote

Psoriasis: US-approved treatments and how Gulf families can access them

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Psoriasis: the short answer

The US FDA has approved nine medicines on this page for psoriasis, each for specific patients. Eight of them are on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.

  • US FDA-approved medicines on this page: Skyrizi, Tremfya, Cosentyx, Taltz, Bimzelx, Sotyktu, Ilumya, Spevigo and Zoryve.
  • Gulf registration (checked 17 October 2026): see each medicine below.
  • Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
  • Price: Quote on request.

What is psoriasis?

Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales, usually on the elbows, knees, scalp, back, face, palms and feet. A problem with the immune system makes skin cells rise to the surface in days instead of a month.[1]

Psoriasis can last a lifetime, with symptoms that come and go. Infections, stress, dry skin and some medicines can make it worse. Some people with psoriasis also develop psoriatic arthritis. It usually occurs in adults and sometimes runs in families.[1]

Treatments include creams, light therapy and medicines. For moderate to severe plaque psoriasis, US-approved biologic injections and oral medicines are used when patients are candidates for systemic therapy or phototherapy. A separate medicine is approved for a rare form called generalized pustular psoriasis.[1, 2, 3, 4]

Psoriasis in the Gulf

A narrative review of psoriasis in Saudi Arabia reported prevalence of up to 5.33% of the population, more men than women affected, onset usually before age 30 and plaque psoriasis as the most common form.[5]

US FDA-approved medicines for psoriasis

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

  • Skyrizi (risankizumab-rzaa)
    FDA-approved for moderate to severe plaque psoriasis in adults and children 6 years and older who are candidates for systemic therapy or phototherapy. It is an injection under the skin. It is also approved for psoriatic arthritis, Crohn's disease and ulcerative colitis.[2]
    Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan, India, Pakistan
  • Tremfya (guselkumab)
    FDA-approved for moderate to severe plaque psoriasis in adults and children 6 years and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. It is an injection under the skin.[8]
    Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, India, Pakistan
  • Cosentyx (secukinumab)
    FDA-approved for moderate to severe plaque psoriasis in adults and children 6 years and older who are candidates for systemic therapy or phototherapy. It is an injection under the skin.[9]
    Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, India, Pakistan
  • Taltz (ixekizumab)
    FDA-approved for moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy. It is an injection under the skin.[10]
    Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman
  • Bimzelx (bimekizumab)
    FDA-approved for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is an injection under the skin.[11]
    Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan, India, Pakistan
  • Sotyktu (deucravacitinib)
    FDA-approved for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is a tablet taken once a day.[3]
    Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan, Turkey, India, Pakistan
  • Ilumya (tildrakizumab-asmn)
    FDA-approved for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is an injection under the skin.[12]
    Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, India
  • Spevigo (spesolimab-sbzo)
    FDA-approved for generalized pustular psoriasis in adults and children 12 years and older who weigh at least 40 kg. It is given by infusion or injection.[4]
    Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
    Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman
  • Zoryve (roflumilast)
    FDA-approved for plaque psoriasis of the scalp and body in adults and children 12 years and older (foam), and other uses listed in the label. It is applied to the skin.[13]
    Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
    Country guides: Saudi Arabia, UAE, Egypt, India

How families in the Gulf can access these medicines

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.[14, 15] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

Who does what

  • Your treating specialist decides whether a medicine is right for the patient and writes the letter.
  • The hospital checks local supply, files any import request, and gives the treatment safely.
  • The national regulator decides whether to approve the import of a medicine that is not registered.
  • The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
  • Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

  • A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
  • Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
  • Recent clinic notes and a list of current medicines
  • For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
  • Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for psoriasis

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Include the country code, for example +966 or +971.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for psoriasis?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Skyrizi, Tremfya, Cosentyx, Taltz, Bimzelx, Sotyktu, Ilumya, Spevigo and Zoryve. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Skyrizi available in Saudi Arabia or the UAE?

Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.

How can a family in the Gulf get Skyrizi?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

What does candidate for systemic therapy mean?

It means your psoriasis is extensive or severe enough that your dermatologist would consider whole-body treatment or light therapy, not only creams. Most US biologic labels use this wording.

Does psoriasis affect joints?

It can. MedlinePlus notes that some people with psoriasis get psoriatic arthritis. Tell your doctor about joint pain or swelling.

Sources for the last two answers: [2, 9] [1]

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

  1. MedlinePlus (US National Library of Medicine): Psoriasis
  2. DailyMed (US National Library of Medicine): Skyrizi (risankizumab-rzaa) US prescribing information, version published 31 July 2026
  3. DailyMed (US National Library of Medicine): Sotyktu (deucravacitinib) US prescribing information, version published 15 July 2026
  4. DailyMed (US National Library of Medicine): Spevigo (spesolimab-sbzo) US prescribing information, version published 18 June 2026
  5. Alzeer et al. Epidemiology and Cutaneous Manifestations of Psoriasis in Saudi Arabia: A Narrative Review. Clin Cosmet Investig Dermatol 2022 (PubMed 35250289)
  6. SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
  7. Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
  8. DailyMed (US National Library of Medicine): Tremfya (guselkumab) US prescribing information, version published 8 June 2026
  9. DailyMed (US National Library of Medicine): Cosentyx (secukinumab) US prescribing information, version published 31 August 2026
  10. DailyMed (US National Library of Medicine): Taltz (ixekizumab) US prescribing information, version published 23 June 2026
  11. DailyMed (US National Library of Medicine): Bimzelx (bimekizumab) US prescribing information, version published 18 June 2025
  12. DailyMed (US National Library of Medicine): Ilumya (tildrakizumab-asmn) US prescribing information, version published 6 October 2026
  13. DailyMed (US National Library of Medicine): Zoryve (roflumilast) US prescribing information, version published 9 October 2026
  14. SFDA: Special Access Program (SAP) guidance, version 1.0
  15. NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products

Related

This page is general health information, not medical advice. It does not replace a consultation with your doctor.

WhatsApp